WO2025213381 - NERATINIB-CYCLODEXTRIN COMPOSITION AND METHOD FOR PREPARING SAME
National phase entry is expected:
Publication Number
WO/2025/213381
Publication Date
16.10.2025
International Application No.
PCT/CN2024/086956
International Filing Date
10.04.2024
Title **
[English]
NERATINIB-CYCLODEXTRIN COMPOSITION AND METHOD FOR PREPARING SAME
[French]
COMPOSITION DE NÉRATINIB-CYCLODEXTRINE ET SON PROCÉDÉ DE PRÉPARATION
Applicants **
HANGZHOU JITAI PHARMACEUTICAL TECHNOLOGY CO., LTD
Inventors
LAI, Qinghai
XU, Jing
ZHANG, Bingxu
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CNIPA
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1735 | |
| EPO | Filing, Examination, Granting | 13196 | |
| Japan | Filing, Examination, Granting | 2269 | |
| South Korea | Filing, Examination, Granting | 2220 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
24,160
Contact Us
Abstract[English]
A composition comprising neratinib, or a pharmaceutically acceptable salt thereof, and hydroxypropyl-β-cyclodextrin, a method for preparing same, and use thereof. Study results show that the composition can not only significantly improve the bioavailability of the active ingredient, but also eliminate food effects and adverse event diarrhea.[French]
L'invention concerne une composition comprenant du nératinib, ou un sel pharmaceutiquement acceptable de celui-ci, et de l'hydroxypropyl-β-cyclodextrine, son procédé de préparation et son utilisation. Les résultats d'étude montrent que la composition peut non seulement améliorer significativement la biodisponibilité du principe actif, mais également éliminer les diarrhées alimentaires et secondaires.